QuotedData

Quoted Data

sign up for emailed equity research
Quick  |   Customised Register
Latest News

Biotech and Healthcare News

US biotech IPO market faces key test after record five pricings

US biotech IPO market faces key test after record five pricings

US biotech IPO market faces key test after record five pricings The currently buoyant US market for biotech new issues faces a key test, after a record five companies priced Nasdaq ...

Syncona accelerates investment in gene therapy portfolio

Syncona accelerates investment in gene therapy portfolio

Syncona accelerates investment in gene therapy portfolio LSE-listed biotech VC fund Syncona (SYNC) has made a significant investment in three of its portfolio companies involved in developing gene therapies, with staged commitments of ...

Alexion files for key drug with priority review voucher

Alexion files for key drug with priority review voucher

Alexion files for key drug with priority review voucher Trust favourite Alexion Pharmaceuticals (Nasdaq: ALXN) yesterday confirmed it had made a US regulatory submission for approval of ALXN1210, its long-acting C5 complement ...

WPCT still at bottom of bio specialist trust league in May

WPCT still at bottom of bio specialist trust league in May

WPCT still at bottom of bio specialist trust league in May Neil Woodford's eponymous Patient Capital Trust (WPCT) has once again ranked at the bottom of the performance league table of biotech/healthcare ...

Arix, Syncona and WPCT look set to reap gains on pending Autolus IPO

Arix, Syncona and WPCT look set to reap gains on pending Autolus IPO

Arix, Syncona and WPCT look set to reap gains on pending Autolus Nasdaq IPO Three LSE-listed health/biotech venture capital investment firms - Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) - ...

FDA fast track review for trust-backed Sage Therapeutics

FDA fast track review for trust-backed Sage Therapeutics

FDA fast track review for trust-backed Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE),  a high conviction idea for two of the biotech sector specialist investment trusts, has confirmed that the US FDA has ...

Trust favourite Genmab hit by trial setback

Trust favourite Genmab hit by trial setback

Trust favourite Genmab hit by trial setback Denmark's Genmab, a widely-held stock among the sector specialist investment trusts, has suffered a major setback in the past week with failure/termination of studies involving ...

Biotech Growth blames large caps for 2017/18 under-performance

Biotech Growth blames large caps for 2017/18 under-performance

Biotech Growth blames large caps for 2017/18 under-performance OrbiMed-managed Biotech Growth Trust (BIOG) blamed an overweight position in large cap stocks for under-performance against the benchmark Nasdaq Biotechnology index (NBI) in ...

WPCT sees £43m drop in value of Prothena stake

WPCT sees £43m drop in value of Prothena stake

WPCT sees £43m drop in value of Prothena stake value Woodford Patient Capital Trust (WPCT) lost £43m on its investment in Prothena last month, following the failure of the company's NEOD001 ...

Biotech Growth doubles down on Biogen and Alexion

Biotech Growth doubles down on Biogen and Alexion

Biotech Growth doubles down on Biogen and Alexion OrbiMed-managed Biotech Growth Trust (BIOG) appears to have increased its already substantial positions in Biogen and Alexion and reduced (or possibly even sold) ...

Contact us

captcha